Rafferty Asset Management
PBYI icon

Rafferty Asset Management’s Puma Biotechnology PBYI Stock Holding History

Rafferty Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-51,137
Closed -$469K – 1299
2021
Q2 		$469K Sell
51,137
-66,580
-57% -$675K ﹤0.01% 1085
2021
Q1 		$1.14M Buy
117,717
+93,487
+386% +$1.04M 0.01% 741
2020
Q4 		$249K Sell
24,230
-65,299
-73% -$661K ﹤0.01% 913
2020
Q3 		$903K Buy
89,529
+40,557
+83% +$413K 0.01% 588
2020
Q2 		$511K Buy
48,972
+31,022
+173% +$321K 0.01% 709
2020
Q1 		$151K Sell
17,950
-134,549
-88% -$1.31M 0.01% 541
2019
Q4 		$1.33M Sell
152,499
-81,063
-35% -$671K 0.02% 480
2019
Q3 		$2.51M Sell
233,562
-118,198
-34% -$1.28M 0.04% 275
2019
Q2 		$4.47M Buy
351,760
+264,904
+305% +$6.1M 0.08% 186
2019
Q1 		$3.37M Buy
+86,856
New +$2.65M 0.05% 195

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Rafferty Asset Management's PBYI Position: Q3 2021 in Review

Rafferty Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2021, closing a stake of 51,137 shares — an estimated $469K sold.

Rafferty Asset Management first reported a position in PBYI in Q1 2019 and held it in 10 quarters. The position peaked at $4.47M in Q2 2019. 115 funds tracked by Wall St. Rank hold PBYI as of Q3 2021.

  • Rafferty Asset Management reported no remaining Puma Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 51,137 Puma Biotechnology shares in Q3 2021, an estimated $469K.
  • Rafferty Asset Management first reported a position in Puma Biotechnology in Q1 2019 and held it in 10 quarters.
  • Rafferty Asset Management's Puma Biotechnology position peaked at $4.47M in Q2 2019.
  • 115 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2021.

Based on Rafferty Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.